Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after looking to partner off its sole clinical-stage asset to no avail this ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

Buckner was speaking last month at Life Science Innovation Northwest, Seattle’s marquee gathering of the biotech industry. Most years, the two-day conference sees scientists, investors and other ...

Gift 5 articles to anyone you choose each month when you subscribe. ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Scientists have long observed this unusual mode of respiration and harnessed it in biotechnology as something of a black box. Now, a Rice-led team has uncovered its mechanism—a breakthrough that ...

Investors considering a purchase of Krystal Biotech Inc (Symbol: KRYS) stock, but cautious about paying the going market price of $169.11/share, might benefit from considering selling puts among ...

Welcome to the Nautilus first quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's pressentation, there will be a question and answer ...